- Home
- BHC vs ARWR Comparison
BHC vs ARWR Comparison
Compare BHC & ARWR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BHC
- ARWR
- Stock Information
- Founded
- BHC N/A
- ARWR 2003
- Country
- BHC Canada
- ARWR United States
- Employees
- BHC N/A
- ARWR N/A
- Industry
- BHC Biotechnology: Pharmaceutical Preparations
- ARWR Biotechnology: Pharmaceutical Preparations
- Sector
- BHC Health Care
- ARWR Health Care
- Exchange
- BHC Nasdaq
- ARWR Nasdaq
- Market Cap
- BHC 3.0B
- ARWR 2.4B
- IPO Year
- BHC N/A
- ARWR 1993
- Fundamental
- Price
- BHC $7.47
- ARWR $19.76
- Analyst Decision
- BHC Hold
- ARWR Buy
- Analyst Count
- BHC 4
- ARWR 11
- Target Price
- BHC $7.25
- ARWR $43.33
- AVG Volume (30 Days)
- BHC 1.5M
- ARWR 1.5M
- Earning Date
- BHC 02-20-2025
- ARWR 02-04-2025
- Dividend Yield
- BHC N/A
- ARWR N/A
- EPS Growth
- BHC N/A
- ARWR N/A
- EPS
- BHC N/A
- ARWR N/A
- Revenue
- BHC $9,474,000,000.00
- ARWR $3,551,000.00
- Revenue This Year
- BHC $10.68
- ARWR $3,402.96
- Revenue Next Year
- BHC $3.66
- ARWR $123.96
- P/E Ratio
- BHC N/A
- ARWR N/A
- Revenue Growth
- BHC 10.91
- ARWR N/A
- 52 Week Low
- BHC $3.96
- ARWR $17.05
- 52 Week High
- BHC $11.46
- ARWR $36.72
- Technical
- Relative Strength Index (RSI)
- BHC 42.13
- ARWR 49.29
- Support Level
- BHC $7.30
- ARWR $17.75
- Resistance Level
- BHC $8.03
- ARWR $19.19
- Average True Range (ATR)
- BHC 0.27
- ARWR 1.02
- MACD
- BHC -0.01
- ARWR 0.10
- Stochastic Oscillator
- BHC 17.35
- ARWR 66.34
About BHC Bausch Health Companies Inc.
Bausch Health Companies Inc is a global specialty pharmaceutical, consumer health, and medical device company with a focus on branded products for the gastroenterology, hepatology, neurology and dermatology markets. The company reports revenue in five segments: Salix; International; Solta Medical; Diversified Products and Bausch + Lomb. It generates maximum revenue from the Bausch + Lomb segment.
About ARWR Arrowhead Pharmaceuticals Inc.
Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting hepatitis B, Alpha-1 Antitrypsin Deficiency, thrombosis and angioedema, clear-cell and renal cell carcinoma, and cardiovascular disease.